FDA advises Advanced Viral Research Corp. that Reticulose IND for HIV (AIDS) is placed on inactive status.MIAMI--(BUSINESS WIRE)--June 9, 1995--Advanced Viral Research Corp. (the "company") (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :ADVR ADVR Association of Directors of Volunteer Resources (Canada) ) announced Friday that following review of the company's Feb. 27, 1995 submission, as of June 1, 1995, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. had placed the company's IND for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. treatment by Reticulose on inactive status until the company provides an adequate response to the FDA's earlier request for certain preclinical information. The company is examining the necessary requirements to have its IND placed on active status again. CONTACT: Advanced Viral Research Corp., Miami William Bregman, 305/374-4847 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion